Cytogen Strengthens Global Partnering by Participating in BioUSA

CytoGen, a liquid biopsy specialist company based on CTC technology, announced on the 5th that it will participate in the '2023 Bio International Convention' to engage in global partnering activities.

'BioUSA' is a bio convention event hosted by the Biotechnology Innovation Organization (BIO) in the United States. This year, it will be held for four days from the 5th to the 8th at the Boston Convention and Exhibition Center. More than 5,000 companies, including pharmaceutical and diagnostic companies from 65 countries, will participate.

CytoGen is a liquid biopsy company that diagnoses cancer based on CTC (circulating tumor cells). Through its unique technology that isolates CTCs without damage, it diagnoses cancer at the RNA, DNA, and protein levels. The technology to recover CTCs is recognized as globally competitive. At this year’s BioUSA, CytoGen is attracting attention from many pharmaceutical, diagnostic companies, and institutional investors, including leading global drug developers. This year, there have been requests for meetings to explore collaboration possibilities across various fields related to circulating tumor cell technology.

As a result of CytoGen’s global marketing activities continuing since last year, the company recently began collaborations with NIH (U.S. National Institutes of Health), Mount Sinai Hospital, and CEPM (Center for Excellence in Precision Medicine, New York).

CytoGen is conducting meetings with major diagnostic companies in the U.S. to cooperate on local diagnostic services. For companion diagnostic service cooperation, it is engaging in partnering activities targeting leading global big pharma companies. It is also contacting numerous research institutions, including large hospitals and university-industry cooperation groups in the U.S., for research collaboration. Through these meetings, CytoGen’s global market entry and portfolio diversification are expected to accelerate.

A CytoGen representative said, "CEO Jeon Byung-hee, along with the heads of research and business development, will directly participate in BioUSA," adding, "We will carry out global partnering activities." He continued, "We will conduct various partnering activities to actively enter the global market, focusing on the U.S. market," and added, "We will accelerate the expansion of CytoGen’s business."